Search Results - "Andrzejewski, Kelly"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Characterization of Endocannabinoid-Metabolizing Enzymes in Human Peripheral Blood Mononuclear Cells under Inflammatory Conditions by Szafran, Brittany N, Lee, Jung Hwa, Borazjani, Abdolsamad, Morrison, Peter, Zimmerman, Grace, Andrzejewski, Kelly L, Ross, Matthew K, Kaplan, Barbara L F

    Published in Molecules (Basel, Switzerland) (01-12-2018)
    “…Endocannabinoid-metabolizing enzymes are downregulated in response to lipopolysaccharide (LPS)-induced inflammation in mice, which may serve as a negative…”
    Get full text
    Journal Article
  2. 2

    Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium by Guttuso, Thomas, Andrzejewski, Kelly L., Lichter, David G., Andersen, Julie K.

    Published in Journal of the neurological sciences (15-07-2019)
    “…Several kinases have been implicated in the pathogenesis of Parkinson's disease (PD), most notably leucine-rich repeat kinase 2 (LRRK2), as LRRK2 mutations are…”
    Get full text
    Journal Article
  3. 3

    Telehealth Management of Parkinson’s Disease Using Wearable Sensors: An Exploratory Study by Heldman, Dustin A., Harris, Denzil A., Felong, Timothy, Andrzejewski, Kelly L., Dorsey, E. Ray, Giuffrida, Joseph P., Goldberg, Barry, Burack, Michelle A.

    Published in Digital biomarkers (01-09-2017)
    “…Background: Parkinson’s disease (PD) motor symptoms can fluctuate and may not be accurately reflected during a clinical evaluation. In addition, access to…”
    Get full text
    Journal Article
  4. 4

    Wearable Sensors in Huntington Disease: A Pilot Study by Andrzejewski, Kelly L, Dowling, Ariel V, Stamler, David, Felong, Timothy J, Harris, Denzil A, Wong, Cynthia, Cai, Hang, Reilmann, Ralf, Little, Max A, Gwin, Joseph T, Biglan, Kevin M, Dorsey, E Ray

    Published in Journal of Huntington's disease (18-06-2016)
    “…The Unified Huntington's Disease Rating Scale (UHDRS) is the principal means of assessing motor impairment in Huntington disease but is subjective and…”
    Get more information
    Journal Article
  5. 5
  6. 6

    Analysis of Participant Withdrawal in Huntington Disease Clinical Trials by Banno, Haruhiko, Andrzejewski, Kelly L, McDermott, Michael P, Murphy, Alyssa, Majumder, Madhurima, de Blieck, Elisabeth A, Auinger, Peggy, Cudkowicz, Merit E, Atassi, Nazem

    Published in Journal of Huntington's disease (01-01-2017)
    “…Excellent retention in Huntington disease (HD) clinical trials is essential for testing new therapies. The stage of disease, cognitive status, and availability…”
    Get more information
    Journal Article
  7. 7
  8. 8

    Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial by Furr Stimming, Erin, Claassen, Daniel O, Kayson, Elise, Goldstein, Jody, Mehanna, Raja, Zhang, Hui, Liang, Grace S, Haubenberger, Dietrich, Adams, Jamie, Beck, Christopher, Chen, Cheryl, Nance, Martha, Testa, Claudia, Huffman, Patricia, Chesire, Amy, Marshall, Frederick, Dayalu, Praveen, Stovall, Angela, Hall, Deborah, Hawkins, Jacob, Ginsburg, Letty, Moore, Henry, Mestre, Tiago, Thompson, Tanya, Connors, Natalie, Rosas, H. Diana, Daley, Allison, Kostyk, Sandra K., Mitchell, Casey, Hellman, Amy, Houston, Sheryl, Buchanan, Danielle, McDonell, Katherine, Factor, Stewart A., Sperin, Elaine, Hurt, Andrea, Wojcieszek, Joanne, Adurogbangba, Mike, Raymond, Lynn A., Corey-Bloom, Jody, Snell, Chase, Blair, Courtney, Sung, Victor, Antonioli, Sophia, Fung, Jacqueline, Laganiere, Simon, Sierra, Luis, Mallonee, William M., Suter, Greg, Bega, Danny, Brown, Zsa Zsa, Elmer, Lawrence, Vollmar, Nancy, del Castillo, Debra, Lin, Yi-Han, Andrzejewski, Kelly, Weigel, Patricia, Hawkins, Trevor, Kirby, Kendra, Retzik-Stahr, Cimmaron, Seeberger, Lauren, Dhall, Rohit, Rassmann, Anja, Luxmore, McKenzie, Scott, Burton, Bulica, Bisena, Boyd, James, Chan, Katherine, McFarland, Nikolaus, Rizer, Kyle, Conlon, Patricia, Suski, Valerie, Rodriguez-Porcel, Federico, Wilson, Sandra, Farrell, Christine, Hunter, David, Houghton, David, Seoane, Sarah, Gibbons, Clare, Rizek, Philippe, Kuprewicz, Robin, Lo, Steven, Cuturic, Miroslav, Segro, Vicki, Greenly, Kate, Revilla, Fredy, Urrea-Mendoza, Enrique, Black, Kevin J., Davis, Thomas, Stover, Natividad, Duker, Andrew, Van Gerpen, Jay, Hedera, Peter, Ondo, William, Anderson, Karen, Bradley, Stephen, Cheung, Ken, Frank, Samuel

    Published in Lancet neurology (01-06-2023)
    “…Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia. To address the ongoing need…”
    Get full text
    Journal Article
  9. 9

    Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials by Andrzejewski, Kelly, Barbano, Richard, Mink, Jonathan

    Published in Basal ganglia (01-08-2016)
    “…We performed a systematic review of the scientific literature assessing the use of exogenous cannabinoids in the treatment of movement disorders including…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease by Tarolli, Christopher G, Andrzejewski, Kelly, Zimmerman, Grace A, Bull, Michael, Goldenthal, Steven, Auinger, Peggy, O'Brien, Michael, Dorsey, E Ray, Biglan, Kevin, Simuni, Tanya

    Published in Journal of Parkinson's disease (01-01-2020)
    “…There is rising interest in remote clinical trial assessments, particularly in the setting of the COVID-19 pandemic. To demonstrate the feasibility,…”
    Get more information
    Journal Article
  12. 12
  13. 13
  14. 14

    Alterations in vestibular function in individuals with cervical dystonia and the effects of botulinum toxin treatment by Andrzejewski, Kelly L., Ma, Shiyang, Owens, Ashley, Bull, Michael T., Biglan, Kevin M., Kanchana, Su, Mink, Jonathan W., McDermott, Michael P., Crane, Benjamin T., Barbano, Richard

    Published in Basal ganglia (01-08-2018)
    “…•Participants with more severe cervical dystonia had vertical perception difficulty.•Vertical perception improves after botulinum toxin treatment for cervical…”
    Get full text
    Journal Article